Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is headquartered in Irvine, California.
Frequently asked questions
What sector does Beta Bionics, Inc. Common Stock (BBNX) operate in?
Beta Bionics, Inc. Common Stock belongs to the Healthcare sector and operates in the Medical Devices industry.
What is Beta Bionics, Inc. Common Stock (BBNX) current stock price?
As of the latest data, Beta Bionics, Inc. Common Stock stock price is $17.78, with a previous close of $18.08. Beta Bionics, Inc. Common Stock lost -$0.30 in the last trading session, representing a -1.66% loss.
What is Beta Bionics, Inc. Common Stock (BBNX) current market capitalization?
Beta Bionics, Inc. Common Stock market cap is approximately 799.92 million.
What is Beta Bionics, Inc. Common Stock (BBNX) Earnings Per Share (EPS)?
The trailing EPS is -$1.53, and the forward EPS is -$2.32.
What is Beta Bionics, Inc. Common Stock (BBNX) EBITDA?
Beta Bionics, Inc. Common Stock EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -24.46 million.
Does Beta Bionics, Inc. Common Stock (BBNX) pay dividends?
No. Beta Bionics, Inc. Common Stock does not pay a dividend.
How did Beta Bionics, Inc. Common Stock (BBNX) perform in its most recent earnings report?
In the last report (June 30, 2026), Beta Bionics, Inc. Common Stock posted an EPS surprise of 14.52% and a revenue surprise of 1.66%.
What is Beta Bionics, Inc. Common Stock (BBNX) beta (volatility) score?
Beta Bionics, Inc. Common Stock has a beta of 0.706, indicating lower volatility than the overall market.
